Cargando…
Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif
This study aims to analyze the epidemiological, clinical, therapeutic and evolutionary profile of ocular manifestations in patients with Behçet’s disease. We conducted a retrospective, descriptive study of the medical records of 121 patients managed by specialists with expertise in this disease over...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The African Field Epidemiology Network
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711680/ https://www.ncbi.nlm.nih.gov/pubmed/31489094 http://dx.doi.org/10.11604/pamj.2019.33.116.17111 |
_version_ | 1783446550341484544 |
---|---|
author | Razzak, Amine Kassimi, Anass Mchachi, Adil Benhmidoune, Leila Chakib, Abderrahim Rachid, Rayad Elbelhadji, Mohamed Amraoui, Abdelouahed Elkabli, Hassan |
author_facet | Razzak, Amine Kassimi, Anass Mchachi, Adil Benhmidoune, Leila Chakib, Abderrahim Rachid, Rayad Elbelhadji, Mohamed Amraoui, Abdelouahed Elkabli, Hassan |
author_sort | Razzak, Amine |
collection | PubMed |
description | This study aims to analyze the epidemiological, clinical, therapeutic and evolutionary profile of ocular manifestations in patients with Behçet’s disease. We conducted a retrospective, descriptive study of the medical records of 121 patients managed by specialists with expertise in this disease over a period of one year and a half between January 2015 and June 2016. The average age of patients was 35 years, 63.6% of patients were male, ocular involvement was inaugural in 24% of cases. Patients had anterior uveitis (7.4%), posterior uveitis (15.7%), vasculitis (19%), irido-crystalline synechias (17.5%), macular edema (7.4%), optic atrophy (4.1%), papillary edema (2.5%) and peripheral retinal ischemia (1.7%). In our series, 41.3% of patients were under colchicine, 23.1% under oral corticosteroids, 9% under intravenous corticosteroids, 4.9% under topical corticosteroids, 8.2% under immunosuppressive drugs and 5.8% under vitamin K antagonists. After an average follow-up of 1 year, 40% of patients had stable visual acuity while receiving treatment, 23% had a significant decrease in visual acuity and 5% of cases had complete vision loss. Adequate therapy enables quick containment of the infection and decreases the frequency and severity of recurrences, thus leading to an improvement of the visual prognosis in our patients compared with outcomes in some previous case serie. |
format | Online Article Text |
id | pubmed-6711680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The African Field Epidemiology Network |
record_format | MEDLINE/PubMed |
spelling | pubmed-67116802019-09-05 Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif Razzak, Amine Kassimi, Anass Mchachi, Adil Benhmidoune, Leila Chakib, Abderrahim Rachid, Rayad Elbelhadji, Mohamed Amraoui, Abdelouahed Elkabli, Hassan Pan Afr Med J Case Series This study aims to analyze the epidemiological, clinical, therapeutic and evolutionary profile of ocular manifestations in patients with Behçet’s disease. We conducted a retrospective, descriptive study of the medical records of 121 patients managed by specialists with expertise in this disease over a period of one year and a half between January 2015 and June 2016. The average age of patients was 35 years, 63.6% of patients were male, ocular involvement was inaugural in 24% of cases. Patients had anterior uveitis (7.4%), posterior uveitis (15.7%), vasculitis (19%), irido-crystalline synechias (17.5%), macular edema (7.4%), optic atrophy (4.1%), papillary edema (2.5%) and peripheral retinal ischemia (1.7%). In our series, 41.3% of patients were under colchicine, 23.1% under oral corticosteroids, 9% under intravenous corticosteroids, 4.9% under topical corticosteroids, 8.2% under immunosuppressive drugs and 5.8% under vitamin K antagonists. After an average follow-up of 1 year, 40% of patients had stable visual acuity while receiving treatment, 23% had a significant decrease in visual acuity and 5% of cases had complete vision loss. Adequate therapy enables quick containment of the infection and decreases the frequency and severity of recurrences, thus leading to an improvement of the visual prognosis in our patients compared with outcomes in some previous case serie. The African Field Epidemiology Network 2019-06-14 /pmc/articles/PMC6711680/ /pubmed/31489094 http://dx.doi.org/10.11604/pamj.2019.33.116.17111 Text en © Amine Razzak et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Series Razzak, Amine Kassimi, Anass Mchachi, Adil Benhmidoune, Leila Chakib, Abderrahim Rachid, Rayad Elbelhadji, Mohamed Amraoui, Abdelouahed Elkabli, Hassan Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif |
title | Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif |
title_full | Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif |
title_fullStr | Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif |
title_full_unstemmed | Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif |
title_short | Œil et Maladie de Behçet: profil épidémiologique, clinique, thérapeutique et évolutif |
title_sort | œil et maladie de behçet: profil épidémiologique, clinique, thérapeutique et évolutif |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711680/ https://www.ncbi.nlm.nih.gov/pubmed/31489094 http://dx.doi.org/10.11604/pamj.2019.33.116.17111 |
work_keys_str_mv | AT razzakamine œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif AT kassimianass œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif AT mchachiadil œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif AT benhmidouneleila œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif AT chakibabderrahim œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif AT rachidrayad œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif AT elbelhadjimohamed œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif AT amraouiabdelouahed œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif AT elkablihassan œiletmaladiedebehcetprofilepidemiologiquecliniquetherapeutiqueetevolutif |